MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position Evaluation of Strategic Alternatives is Ongoing As of March 31, 2025, the Company had $20.5 million in cash and cash equivalents with no outstanding debt. About MEI Pharma MEI Pharma, Inc. (Nasdaq: MEIP) is a pharmaceutical company with a portfolio of several drug candidates that may offer novel and differentiated cancer therapies. The drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor. For more information ...